What Do You Need to Know About Humana (HUM) Before Investing?

By Ken Smith • Thursday, December 04 10:04 • Permanent Link

Humana logged a -1.4% change during today's morning session, and is now trading at a price of $253.45 per share. The S&P 500 index moved -0.0%. HUM's trading volume is 213,441 compared to the stock's average volume of 1,910,042.

Humana trades -11.57% away from its average analyst target price of $286.62 per share. The 24 analysts following the stock have set target prices ranging from $215.0 to $353.0, and on average have given Humana a rating of hold.

Anyone interested in buying HUM should be aware of the facts below:

Humana's current price is 45.3% above its Graham number of $174.42, which implies that at its current valuation it does not offer a margin of safety
Humana has moved -9.2% over the last year, and the S&P 500 logged a change of 12.8%
Based on its trailing earnings per share of 10.69, Humana has a trailing 12 month Price to Earnings (P/E) ratio of 23.7 while the S&P 500 average is None
HUM has a forward P/E ratio of 15.1 based on its forward 12 month price to earnings (EPS) of $16.84 per share
Its Price to Book (P/B) ratio is 1.65 compared to its sector average of None
Humana Inc. provides medical and specialty insurance products in the United States.
Based in Louisville, the company has 65,680 full time employees and a market cap of $30.48 Billion. Humana currently returns an annual dividend yield of 1.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.